266 related articles for article (PubMed ID: 38175151)
1. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.
Xie Y; Choi T; Al-Aly Z
JAMA Intern Med; 2023 Jun; 183(6):554-564. PubMed ID: 36951829
[TBL] [Abstract][Full Text] [Related]
3. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
4. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
Ranard BL; Chow CC; Megjhani M; Asgari S; Park S; Vodovotz Y
J Med Virol; 2023 Jun; 95(6):e28854. PubMed ID: 37287404
[TBL] [Abstract][Full Text] [Related]
7. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
Yan M; Xie M; Zhu S; Li H; Li S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y
JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
[TBL] [Abstract][Full Text] [Related]
11. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
12. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.
Congdon S; Narrowe Z; Yone N; Gunn J; Deng Y; Nori P; Cowman K; Islam M; Rikin S; Starrels J
Sci Rep; 2023 Nov; 13(1):19688. PubMed ID: 37951998
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
medRxiv; 2023 Jun; ():. PubMed ID: 37425934
[TBL] [Abstract][Full Text] [Related]
14. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals.
Smith-Jeffcoat SE; Biddle JE; Talbot HK; Morrissey KG; Stockwell MS; Maldonado Y; McLean HQ; Ellingson KD; Bowman NM; Asturias E; Mellis AM; Johnson S; Kirking HL; Rolfes MAR; Olivo V; Merrill L; Battan-Wraith S; Sano E; McLaren SH; Vargas CY; Goodman S; Sarnquist CC; Govindaranjan P; Petrie JG; Belongia EA; Ledezma K; Pryor K; Lutrick K; Bullock A; Yang A; Haehnel Q; Rao S; Zhu Y; Schmitz J; Hart K; Grijalva CG; Salvatore PP
Clin Infect Dis; 2024 May; 78(5):1175-1184. PubMed ID: 37963102
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
Ann Intern Med; 2023 Dec; 176(12):1577-1585. PubMed ID: 37956428
[TBL] [Abstract][Full Text] [Related]
18. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
20. Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.
Birabaharan M; Martin TCS
Am J Emerg Med; 2022 Nov; 61():235.e5-235.e6. PubMed ID: 35970690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
